January 2018January 2018
New Product - Zinplava
Zinplava (bezlotoxumab (rch)) is a specific fully human monoclonal antibody that binds with high affinity to Clostridium difficile (C. difficile) toxin B and neutralises its activity by preventing it from binding to host cells. C. difficile colonises and infects the large intestine. Zinplava prevents C. difficile infection (CDI) recurrence by providing enhanced passive immunity against toxin produced by the outgrowth of persistent or newly acquired C. difficile spores. Zinplava is indicated for the prevention of recurrence of CDI in adults 18 years or older at high risk for recurrence of CDI who are receiving antibiotic therapy for CDI. Zinplava is not indicated for the treatment of CDI. Zinplava is not an antibacterial drug. Zinplava should only be used in conjunction with antibacterial drug treatment of CDI. The safety and efficacy of repeat administration of Zinplava in patients with CDI have not been studied. Zinplava is contraindicated with hypersensitivity to bezlotoxumab or to any of the inactive ingredients. Zinplava concentrated injection (25 mg/mL) is supplied in one single dose vial containing 1000 mg/40 mL.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au